BTIG raised the firm’s price target on Abivax (ABVX) to $120 from $112 and keeps a Buy rating on the shares. Based on the data from the ABTECT 1 and ABTECT 2 trials, which met primary endpoints, the firm increased its price target on the shares after increasing obefazimod penetration in ulcerative colitis to 40% from 35%, corresponding to 93,000 patients on Tx at peak in the U.S. The firm added that the data supports broad use across the Tx paradigm, with maintenance data expected in 2Q26.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Abivax’s Obefazimod: Promising Clinical Results and Market Potential Drive Buy Rating
- Abivax announces ABTECT 1, ABTECT 2 trials met primary endpoint
- Promising Phase 2b Results and Competitive Positioning Support Buy Rating for Abivax’s Obefazimod
- Abivax price target raised to $114 from $95 at Citizens JMP
- One new option listing on September 18th